Metformin Oresund Pharma

Metformin Hydrochloride, the active ingredient in Metformin Oresund Pharma, is a biguanide presented as an oral tablet for oral use. It is used to lower elevated blood glucose levels in adults with type 2 diabetes mellitus and may be prescribed as part of a comprehensive diabetes management plan.

GNH USA supplies Metformin Oresund Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Oresund Pharma belongs to the biguanide class and is employed to improve glycaemic control in disorders of glucose metabolism. - Type 2 diabetes mellitus: reduces hepatic glucose production and enhances peripheral insulin sensitivity to lower fasting and post‑prandial blood glucose. - Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes by improving insulin sensitivity. - Polycystic ovary syndrome: may improve insulin resistance and assist in restoring ovulatory cycles.

Metformin Oresund Pharma may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening accumulation of lactate, especially in renal impairment. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Vitamin B12 deficiency: may develop with long‑term use. - Hypoglycaemia: rare when used alone, more common with concomitant insulin or sulfonylureas. - Acute pancreatitis: very uncommon but reported.

Metformin Oresund Pharma requires careful patient assessment and monitoring to minimise risks. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: avoid use in patients with significant liver disease. - Contraindicated in severe renal impairment: discontinue if eGFR falls below 30 mL/min/1.73 m². - Elderly patients: start at lower doses and monitor for accumulation. - Alcohol consumption: advise limiting intake to reduce lactic acidosis risk. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Oresund Pharma can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol: potentiates lactic acidosis. - Carbamazepine: may reduce metformin effectiveness. - Rifampin: can increase metformin clearance.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemic symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors: monitor renal function and potassium. - NSAIDs: may impair renal function, increasing metformin exposure. - Digoxin: watch for altered plasma levels when combined with metformin.